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Abstract: The US outbreak of B.anthracis infection in 2001 and subsequent cases in the US and
Europe demonstrate that anthrax is a continuing risk for the developed world. While several
bacterial components contribute to the pathogenesis of B. anthracis, production of lethal toxin (LT) is
strongly associated with the development of hypotension and lethality. However, the mechanisms
underlying the cardiovascular instability LT produces are unclear. Some evidence suggests that
LT causes shock by impairing the peripheral vasculature, effects consistent with the substantial
extravasation of fluid in patients dying with B. anthracis. Other data suggests that LT directly
depresses myocardial function. However a clinical correlate for this latter possibility is less evident
since functional studies and post-mortem examination in patients demonstrate absent or minimal
cardiac changes. The purposes of this review were to first present clinical studies of cardiac
functional and histologic pathology with B. anthracis infection and to then examine in vivo, in vitro,
and ex vivo preclinical studies of LT’s myocardial effects. Together, these data suggest that it is
unclear whether that LT directly depresses cardiac function. This question is important for the
clinical management and development of new therapies for anthrax and efforts should continue
to be made to answer it.
Keywords: Bacillus anthracis; anthrax; lethal and edema toxins; cardiovascular dysfunction;
shock; treatment
1. Introduction
The development of shock in patients with Bacillus anthracis (B. anthracis or anthrax) infection
appears associated with a particularly poor prognosis. In contrast to mortality rates of 40% to 50%
with shock complicating other types of bacterial infection, in recent anthrax outbreaks in the US and
Europe, mortality rates in patients with shock have been greater than 75% [1–4]. B. anthracis produces
two toxins, lethal and edema toxins (LT and ET respectively), as well as other components (e.g.,
non-toxin proteases and cell wall components) which may contribute to its pathogenesis [5]. Of these
components however, production of LT has been most strongly associated with the development of
hypotension and subsequent lethality. Despite increasing insights into LT’s intracellular effects, the
mechanisms underlying the cardiovascular instability it produces are unclear.
On the other hand, some experimental data have also suggested that LT produces shock by
impairing the peripheral vasculature via either disruption of endothelial barrier or vascular smooth
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muscle function [6–10]. Such effects would be very consistent with the substantial extravasation of
fluid and resistance to conventional hemodynamic support that has been noted to occur in patients
and animals dying with B. anthracis infection [1,2,11,12]. On the other hand, some experimental
data has also suggested that LT produces shock by directly depressing myocardial systolic and/or
diastolic function [13–17]. However a clinical correlate to this possibility is less evident. Although
data regarding cardiac function in patients with B. anthracis are limited, there are several striking
examples of patients dying with anthrax associated shock but in whom echocardiographic and even
pulmonary arterial catheter measures of myocardial function close to the time of death were reported
to be normal [18,19]. Also, while LT has been reported to depress myocardial function in animal
models, these observations have sometimes been based on calculated reductions in cardiac output
(CO) or left ventricular ejection fraction (LVEF) measured with echocardiography [10,13,20]. These
studies can be difficult to interpret since the influence of preload or afterload changes on heart
volumes, CO or LVEF have typically not been accounted for.
Given the likely important contribution LT makes to the development of shock during
B. anthracis infection, a clearer understanding of whether it does in fact directly depress myocardial
function has important clinical and research implications. First, it would emphasize the need for
practitioners to directly monitor myocardial function in patients with invasive anthrax infection and
cardiovascular instability and to consider the early use of vasoactive agents with strong inotropic
effects. Second, it would highlight the need for research directed at identifying mechanisms
underlying LT induced myocardial defects and the agents best able to correct those. After a short
description of LT and its intracellular actions, the purpose of the present review is to first examine
whether clinical data implicates cardiac dysfunction in the pathogenesis of B. anthracis infection and
to then summarize in vivo, in vitro, and ex vivo preclinical data investigating LT’s potential effects on
myocardial function.
2. Lethal Toxin and Its Intracellular Actions
Lethal toxin is a binary type toxin comprised of protective antigen (PA), the component necessary
for toxin uptake by host cells, and lethal factor (LF), the toxic component [9,21]. During infection, both
PA and LF are released into the circulation. A PA protomer (PA83) binds to one of at least two receptors
on host cells; tumor endothelial marker-8 (TEM-8) or capillary morphogenesis gene-2 (CMG2), also
termed anthrax toxin receptors 1 or 2 (ANTR-1 or ANTR-2), respectively. Both receptors are widely
distributed in host tissues including the heart and blood vessels although some data suggests that
CMG2 binding plays a predominant role in LT’s effects during infection [9]. The PA83 protomer then
undergoes furin cleavage, and the remaining bound monomer (PA63) forms heptamers or octamers
that up to three or four LF molecules (or edema factor [EF] molecules, the toxic moiety of ET) can
bind to. This complex then undergoes endocytosis and as the endosomal pH decreases, the LF (and
EF) molecules are released into the host cell’s cytosol where they can act.
Lethal factor is a metalloprotease which has two primary actions: it cleaves mitogen activated
protein kinase kinase (MAPKK) pathways 1 to 4, 6 and 7, thus disrupting key host stress kinase
pathways (ERK 1 and 2, p38 and JNK 1) and; it activates the host inflammasome NLRP3, resulting
in upregulation of caspase-1 and the production of IL-1 and IL-12 [22,23]. Evidence suggests that
both of these actions have the potential to produce relatively acute and direct myocardial injury and
dysfunction [24,25].
3. Effects of B. Anthracis Infection on the Heart in Clinical Studies
As noted above, studies investigating myocardial function in patients with B. anthracis are very
limited. Furthermore, any abnormalities that have been reported cannot be attributed to LT alone
given the multiple other bacterial components associated with this bacterium that could alter the
heart [5]. Other types of gram-positive bacterial infection have been associated with myocardial
depression in the absence of LT [26]. It is still worthwhile though to consider what is known about
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the myocardial effects of B. anthracis infection in patients as a basis for considering what LT might
contribute to. In this context, clinical data are primarily comprised of histopathology findings from
patients dying with anthrax infection and of functional studies available in a small number of isolated
case reports.
The largest group of anthrax cases for which pathological data are available comes from the
outbreak of inhalational infection in Sverdlovsk, Russia in 1979, which affected at least 94 people,
64 of whom died [11,12]. This outbreak resulted from the inadvertent release of anthrax spores from a
bioweapons factory. Quantitative histological examination of 41 autopsy cases from this outbreak was
noteworthy for extensive bacterial involvement of the mediastinum and mediastinal lymph nodes
with associated tissue edema, hemorrhage, fibrin deposition, and vasculitis, and with spread of these
changes to the intestines and central nervous system (CNS) in some cases. Large pleural effusions and
retrograde lymphatic spread of bacteria producing pneumonia were observed to have likely resulted
in respiratory compromise. Investigators speculated that much of the changes noted were related
to initial foci of bacteria releasing LT and ET, which in turn produced loss of endothelial integrity,
edema formation, hemorrhage, and subsequently apoptotic cell death. Despite extensive changes in
several organs though, examination of heart tissue in 25 patients demonstrated bacteria in only nine
specimens. Furthermore, there were no specific cardiac microscopic findings noted, with exception of
a few cases showing myocyte hypereosinophilia and rare focal-contraction band necrosis attributed
to agonal hypotension and hypoxemia.
Another group of clinical autopsies (five) or tissue samples (three lung biopsies) available
for review comes from the outbreak of inhalational anthrax affecting 11 patients in the United
States in 2001 [1,27]. This outbreak resulted from the dissemination of anthrax contaminated
letters. While tissue examination was reported individually from several of these cases, a systematic
analysis was also performed of all eight cases. This analysis reported that the major pathological
and histopathological findings came from immunohistochemistry (IHC) staining which showed
B. anthracis cell wall and capsule fragments in mediastinal lymph nodes, soft tissue, and pleura and
in the blood vessels or sinusoids of lung, liver, spleen, and intestines. Notably, findings related to
the heart in patients with autopsies were not specifically recorded, other than that rare bacteria were
present in coronary vessels. Individual reports from these five cases concentrated on mediastinal
(lymph nodes and soft tissue), lung, intestinal and CNS tissue examination and none reported
findings specifically regarding the heart or myocardium [28–31].
In three autopsy cases reported from an outbreak of B. anthracis among wool workers, there was
no mention of abnormal myocardial changes on microscopic examination in two, while moderate
sub-endocardial hemorrhage was noted in one [32]. In a review of 33 autopsy cases, while microscopic
changes were described in the lung, gastrointestinal tract, lymph nodes, spleen, liver, and kidney,
there was no report of abnormal findings on heart examination [33].
Thus in these reports, there appeared to be limited histologic evidence of myocardial injury in
patients dying with B. anthracis infection. However, this does not exclude the possibility that electron
microscopy or other histologic methods might not have shown evidence of myocardial involvement.
Functional cardiac studies from patients with B. anthracis infection are very limited. Over the
past 15 years there have been approximately 80 cases of inhalational, gastrointestinal, or injectional
anthrax (i.e., the three forms of infection associated with high mortality rates) reported to have
occurred in the US or Europe [1,2,34–38]. Of these, 48 appear to have actually been noted in the
literature either in individual case reports or case series. Among these reports, descriptions of
functional cardiac studies have been provided in only 11 patients. The most detailed study was
of a 61 year old woman, who presented during the 2001 B. anthracis outbreak with respiratory
distress with bilateral pleural effusions, peri-hilar infiltrates and a widened mediastinum on chest
radiograph [18]. Echocardiogram at presentation showed normal left ventricular function and wall
motion, slight aortic regurgitation, a small pericardial effusion and an aneurysm of the ascending
aorta. EKG showed sinus tachycardia but was otherwise normal and a troponin level was negative.
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Although treated initially with furosemide for presumed heart failure, the patient’s respiratory and
hemodynamic status rapidly worsened and she was intubated and mechanically ventilated. A
pulmonary artery catheter was placed which showed a right atrial pressure of 4 mmHg (reference
range 0–6 mmHg), right ventricular pressure of 17/5 mmHg (reference range 20–30/5–15 mmHg) and
a pulmonary artery pressure of 20/10 mmHg (reference range of 20–30/5–15 mmHg). Pulmonary
artery occlusion pressure (PAOP) was unobtainable and cardiac output was not reported. The
patient then received volume resuscitation for hemodynamic instability and vasopressors were
ultimately required. After initial testing, differential diagnosis included dissecting aortic aneurysm,
severe community acquired pneumonia, vasculitis, or anthrax, but not heart failure. Blood cultures
from admission grew B. anthracis. Echocardiography on day 2 showed an increase in the size
of the pericardial effusion. The patient’s respiratory status continued to worsen and a repeat
echocardiogram on day 3 showed further increase in the pericardial effusion and mild to moderate
right atrial and ventricular collapse during diastole. Cardiac index was 2.6 L/min/m2 (reference
range 2.4 to 4.0 L/min/m2), systemic vascular resistance was 1131 dynes¨ s¨m2/cm5 (reference range
900–1400 dynes¨ s¨m2/cm5) and a pulmonary capillary wedge pressure of 13 mmHg (reference
range 6–12 mmHg) with no evidence of equalization of pressures. A follow-up echocardiogram
5 h later showed persistent collapse of the right atrium and ventricle concerning for tamponade.
An attempted pericardiocentesis was unsuccessful and the patient expired. Autopsy showed a
hemorrhagic pericardial effusion.
Other clinical reports of cardiac assessment in anthrax patients provide less information.
Echocardiography was performed close to the time of admission in a 44 year old male patient
subsequently found to have inhalational anthrax related to infected animal hides and who presented
with two to three days of fever, respiratory symptoms, and evidence of pneumonia with a
loculated pleural effusion [35]. Echocardiography showed a slightly dilated and mild to moderately
hypertrophied left ventricle with a mildly hypokinetic apex, contractility at the lower limits of
normal for the rest of the ventricle and a small pericardial effusion (personal communication with
author). This patient developed progressive respiratory distress related to his pulmonary disease and
hemodynamic compromise requiring mechanical ventilation and circulatory support but additional
echocardiographic findings were not reported. In a 61 year old man with inhalational anthrax of
unclear origin who presented with progressive respiratory failure requiring mechanical ventilation
but who remained hemodynamically stable, an echocardiogram on day six of hospitalization showed
left ventricular hypertrophy, mildly decreased LVEF (40%), no wall motion abnormality, an estimated
pulmonary artery systolic pressure of 17 mmHg, probable decreased right ventricular function and
no pericardial effusion (personal communication with author) [38]. A cardiac troponin I (cTnI) level
close to the time of the echocardiogram was 0.025 ng/mL (reference value <0.034 ng/mL). The patient
survived but no follow up echocardiogram was performed. A 55 year old man with severe injectional
anthrax involving his thigh and peritoneum developed fulminant septic shock that progressed
to cardiac arrest and was resuscitated after 12 min of CPR. A transesophageal echocardiogram
performed on day 2 of hospitalization, after his cardiac arrest and while on high dose vasopressors
and with systemic acidosis, was reported as normal [19]. This patient died on day 4 of hospitalization
with progressive multi-organ failure but no subsequent echocardiogram was provided. A 24 year old
woman presenting with nine days of progressive fatigue, fever, abdominal pain, and shock was later
found to have gastrointestinal anthrax. An echocardiogram completed at admission was reportedly
normal [37]. Finally, a survey of physicians that cared for 27 patients with injectional anthrax
investigated multiple clinical end points pertaining to physical and laboratory findings, management
and outcome. In this study, four patients reportedly had echocardiography while one patient had
lithium dilution measures and another pulse contour cardiac output analysis [2]. Of these patients,
three were noted to have normal echocardiograms, while the remaining three, all non-survivors, were
reported to have abnormal findings with their respective tests, but actual data were not recorded.
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Other case reports of clinical anthrax have not included any functional or histopathologic cardiac
data [27,39–44].
Table 1 summarizes cardiac findings from the clinical studies. Overall, these studies do not
provide a clear picture as to whether B. anthracis infection is or is not associated with myocardial
depression. It is unknown whether the limited data available regarding functional cardiac studies
in clinical reports is the result of incomplete testing or because the results of such testing were
unremarkable and not thought relevant for reporting.
Table 1. Summary of cardiac findings or the absence of any reported findings from clinical
anthrax studies.
Publication Number of Patients Type of AnthraxInfection
Clinical or Histopathological
Cardiac Findings
Albrink et al. 1960 [32] 3 Inhalational
Moderate subendocardial
hemorrhage into myocardium of
left ventricle noted at autopsy
Abramova et al. 1993 [11]
Grinberg et al. 2001 [12] 42 Inhalational
No specific cardiac
histopathological findings were
noted. However, occasional cases
showed myocyte
hypereosinophilia and rare focal
contraction band necrosis
attributed to agonal hypotension
and hypoxemia
Mayer et al. 2001 [44] 2 Inhalational No functional cardiacassessment completed
Borio et al. 2001 [29] 2 Inhalational ECG showing atrial fibrillation,no other specific findings noted
Jernigan et al. 2001 [1] 10 * Inhalational
ECG showing atrial fibrillation
noted in one of the four patients
not reported as isolated cases
Bush et al. 2001 [28] 1 Inhalational No gross cardiac abnormalities onautopsy found
Barakat et al. 2002 [31] 1 Inhalational No functional cardiacassessment completed
Mina et al. 2002 [18] 1 Inhalational
Echocardiogram showed normal
LV function at presentation with
small pericardial effusion that



















Walsh et al. 2007 [35] 1 Inhalational Echocardiogram showingminimal pericardial effusion
Klempner et al. 2010 [37] 1 Gastrointestinal
Transthoracic echocardiogram
showed a normal ejection
fraction, no valvular vegetations
and findings consistent with right
atrial volume overload, and right
ventricular systolic hypertension
Doganay et al. 2010 [40] 22 Cutaneous No functional cardiacabnormalities noted
Popescu et al. 2011 [41] 2 Cutaneous No functional cardiacabnormalities noted
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Table 1. Cont.
Publication Number of Patients Type of AnthraxInfection
Clinical or Histopathological
Cardiac Findings
Powell et al. 2011 [42] 1 Injectional No functional cardiacabnormalities noted
Gruno et al. 2012 [43] 3 Injectional No functional cardiacabnormalities noted
Russel et al. 2013 [19] 2 Injectional
Transesophageal echocardiogram
reported normal in setting of
fulminant septic shock
Booth et al. 2014 [2] 27 Injectional
Of nine patients reported, three
had dysfunction based on
echocardiography, lithium
dilution or pulse contour cardiac
outputs, and one had an elevated
troponin. Other patients had no
evidence of abnormal cardiac
function (see section 3)
Sprenkle et al. 2014 [38] 1 Inhalational
Echocardiogram showed left
ventricular hypertrophy with EF
of 40%, normal estimated
pulmonary artery pressure,
probable decreased right
ventricular function and no
pericardial effusion
* This review included six other patients in this table described as isolated cases including reports by Mayer,
Borio, Bush and Mina; ** This review included patients in this table described in case reports by Jernigan
and Barakat.
4. Effects of LT on the Heart in in vivo, in vitro and ex vivo Studies
Following the identification of LT (and ET) by Smith et al. in 1955 and up until the early
1970s, there were multiple studies performed by several groups employing small and large animal
models examining LT’s physiologic effects, including its cardiopulmonary ones [45,46]. While some
of these studies did examine myocardial histology, and many measured blood pressure and heart rate,
there were no studies that employed techniques permitting an investigation of the potential direct
myocardial effects of LT. In these investigations, most of which employed a LT challenge administered
as an intravenous (i.v.) bolus, the predominant cardiopulmonary changes noted were disruption of
the pulmonary arterial endothelium with attendant edema and hemorrhage [47,48]. Hypotension did
not occur until very close to the time of death in these models and was attributed primarily to already
evident pulmonary dysfunction. Following these early studies, there was limited research examining
the cardiovascular effects of LT until the outbreak of infection in the US in 2001. Notable in that
outbreak in which patients received aggressive ICU support when needed, and at odds with earlier
conclusions regarding LT’s potential cardiovascular effects, was that shock occurred well before death
in some non-survivors and was not the result of respiratory failure [1]. However, as described above,
shock in patients appeared associated with a particularly poor outcome when compared to other
types of bacteria.
Following the 2001 outbreak, there was renewed interest in investigating the cardiovascular
effects of LT in both in vivo and in vitro models. One of the first studies to be published in this
regard did not include hemodynamic measures but employed comprehensive histologic examination
in combination with biomarker analysis in mice challenged with LT [49]. This study concluded that
LT produced non-inflammatory hypoxic tissue injury consistent with a state of hypoperfusion that
was tumor necrosis factor α (TNFα) independent. Histology demonstrated minimal myocardial
coagulative necrosis with mild cardiac dilation at 48 h in a few animals. However, creatinine
phosphokinase measures were notably elevated to high levels in some animals. Our group,
employing 24 h LT infusions in rats to better simulate toxin release during infection and measuring
blood pressure continuously with indwelling catheters in awake animals, demonstrated that LT
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produced gradual reductions in blood pressure that were greater in non-survivors than survivors [50].
Lethal toxin did not alter oxygenation or lung or myocardial histology measured on light microscopy.
The development of shock with LT was also not associated with the systemic inflammatory response
a comparably lethal dose of lipopolysaccharide produced. However, neither of these studies directly
examined the effects of LT on myocardial function.
The initial investigations reporting that LT might produce direct myocardial depression were
performed by a group employing echocardiography in Sprague-Dawley rats. In one study, animals
were challenged with LT as an i.v. bolus [13]. Although the LT dose employed was designed
to produce an approximate 50% lethality rate, mean arterial blood pressure (MAP, measured
telemetrically) appeared to decrease markedly over a 6 to 8 h period to less than 30 mmHg and
subsequent measures were not reported. Echocardiography performed from 0 to 2 h, demonstrated
that compared to control animals, LT produced significant increases in both left ventricular systolic
and diastolic areas (LVAs and LVAd respectively) and in the velocity of propagation (Vp), a
surrogate measure of left ventricular compliance. Left ventricular ejection fractions (LVEF) were
reportedly decreased with LT, but calculated values were not provided. It was concluded that LT
had induced acute myocardial dysfunction comparable to fulminant myocarditis and manifested by
marked increases in ventricular compliance. However, the rapid and marked reductions in blood
pressure occurring in the model confound the echocardiographic findings since it is unclear to what
degree they contributed to versus were the result of the cardiac changes noted. In a subsequent
study using a similar LT challenge (i.v. bolus), animals were sacrificed 2 to 5 h after LT and
tissue was taken for histological analysis [51]. Light and electron microscopic examination of lung
tissue from LT challenged animals demonstrated extensive extravascular fluid and fibrin deposition
consistent with pulmonary edema. Unfortunately no analysis was provided of heart tissue and so
it is unknown whether there was a histologic basis either on light or electron microscopy for the
functional myocardial changes the investigators had previously reported on in this same model.
However, examination of liver, trachea, esophagus, kidney, urinary bladder, thyroid, parathyroid,
adrenals, pancreas, pituitary, brain, and bone marrow did not show changes. In another in vivo
study reported by this group, rats had serial blood pressure via non-invasive tail measurements
and echocardiography measures at baseline before and from 12 to 48 h after intraperitoneal (i.p.) LT
challenge [52]. In this study, LT administration was reported to reduce Vp (as opposed to the increases
previously noted), to increase LVAs (but not LVAd) and reduce LVEF. Heart-rate-corrected-velocity
of circumferential fiber shortening (VCFC) was also decreased with LT and was reported to reflect
a reduction in left ventricular contractility. Based in part on their findings with echocardiography
in the rat model, as described next, investigators from this group collaborating with others, did
additional in vivo and in vitro studies to understand how LT might affect heart function at the
cardiomyocyte level.
In one series of studies using cardiomyocytes isolated from normal mice and treated with LT
or from mice challenged 18 h previously with intraperitoneal (i.p.) LT, the investigators reported
that LT inhibited cardiomyocyte peak shortening (PS) and the maximal velocity of shortening
and re-lengthening (˘dL/dt), and increased the time to peak shortening (TPS) and time to 90%
re-lengthening (TR90) [15,53,54]. These changes were associated with an inhibitory effect of LT on
Ca2+ transients within the cardiomyocytes, manifested primarily by a prolongation in Ca2+ decay.
Experiments with either aponycin, an NADPH oxidase inhibitor or with catalase over-expressing
mice, suggested that the inhibitory effects of LT on cardiomyocyte function was in part related to
the production of superoxide and reactive oxygen species (ROS). Other experiments suggested that
these or additional actions by LT produced cardiomyocyte depression via mechanisms involving;
interference with the Ca2+ regulatory proteins SERCA2a and phospholamban (PLB); stimulation
of autophagy and to a lesser extent endoplasmic reticulum (ER) stress; and the production of
mitochondrial membrane or ubiquitin and proteasome defects. However these effects were not
always consistent when the methods of cardiomyocyte exposure to LT were compared. For example,
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while measures 2 h after in vitro LT exposure showed up and down regulation of the Ca2+ regulatory
proteins SERCA2a and phospholamban (PLB) respectively, these proteins were not altered when
measured 18 h after in vivo i.p. LT exposure. Other experiments in this series of studies in knockout
mice suggested that the effects of i.p. LT challenge on cardiomyocyte function were mediated in part
by toll-like receptor-4 (TLR-4). Echocardiography in this experiment showed that while LT in wild
type mice (WT) reduced left ventricular end diastolic dimensions (LVEDD) and left ventricular end
systolic dimensions (LVESD) and calculated fractional shortening and cardiac output, these changes
were smaller in TLR-4 knockout animals.
In another study by members of this group, serial echocardiographic measures in
Sprague-Dawley rats challenged with a minimally lethal i.v. LT bolus demonstrated very early (2
to 4 h after challenge) evidence of diastolic heart failure with pulmonary artery regurgitation and
left atrial dilation, when compared to baseline measurements [16]. Left ventricular ejection fraction
was unchanged with LT challenge in this model. Non-challenged animals serving to control for the
effects of serial echocardiography and anesthetics (baseline, 2, 4, 8, and 24 h after challenge) were not
presented. In data that were compared to a control, LT challenge was noted to increase intracellular
Ca2+ (Ca2+i), an effect that could result in diastolic dysfunction. Consistent with the known effect of
LT on interference with MEK and activation of MAPKs, LT challenge was found to inhibit of MEK7
and JNK1 activity resulting in downstream activation of protein phosphase, dephosphorylation of
PLB, and interference with SERCA2a regulated Ca2+ uptake by the sarcoplasmic reticulum. The
investigators in this study suggested that the early diastolic dysfunction that was observed with
LT may have a clinical correlate in the pleural and pericardial effusions and pulmonary edema
sometimes noted in patients with B. anthracis infection.
While this series of studies is informative, limited data was presented linking the mechanisms
speculated to underlie LT’s depressant effects, to the echocardiographic changes (increased or
decreased Vp and increased LVAs alone or in combination with increased LVAd) or to the hypotension
and lethal effects, LT was originally reported to produce [13,15,52–55]. While survival was modestly
prolonged with an i.p. LT challenge in catalase overexpressing mice compared to wild type animals,
these changes were not reported to be significant and no measures of in vivo cardiac function were
described. Also, in the echocardiography data that was presented in the studies comparing TLR-4
knockout and WT mice, LT was associated with decreases in LVEDD and LVESD, and not the
increases (either in both or only the latter) that would have been expected based on the original rat
experiments showing increases in LVAd and LVAs [13,52]. Overall, these studies certainly suggest
that LT may have important myocardial effects. However they also highlight how the effects of
challenge with biological agents in animal models may vary based on the method of challenge and
the model employed for study.
Studies by another group have also suggested that direct myocardial depression has a role in
LT associated lethality [49]. An initial study noted above in mice challenged with i.p. or i.v. LT,
while not showing marked myocardial changes on histology, noted significantly increased creatine
phosphokinase levels in animals consistent with myocardial injury. In a subsequent study, this group
measured three more selective markers of cardiac injury including myoglobin, cardiac troponin-I
(cTnI) and heart type fatty acid binding protein (H-FABP) for up to 120 h after lethal i.p. LT challenge
in C57BL/6J mice [14]. They found substantial increases in all three of these markers within the first
15 h after toxin challenge that persisted for up to 48 h. As opposed to light microscopy of heart tissue
which showed little change with LT in the model, electron microscopy showed endothelial necrosis,
inter-fiber edema with cell debris, altered endothelial junctions, and fragmented myofilaments.
Despite these biochemical and ultrastructural changes though, echocardiography of animals 24 h
after LT challenge only showed a trend in reduced LVEF. However, the striking and rapid increases in
cardiac-selective enzymes with LT in the study suggested that the heart might be an early target of LT
in this mouse model. This possibility was explored further in studies employing mice engineered
to either lack or to over-express CMG2 in selected tissues [10]. In these elegant studies in mice
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challenged with i.p. LT, selective deletion of CMG2 in cardiac and vascular smooth muscle tissue
together was highly protective and deletion in cardiac tissue alone was still protective but less so.
CMG2 deletion in endothelial tissue alone was not protective. Consistent with this, increases in
cTnI and decreases in LVEF with LT challenge were reduced or not evident in mice lacking CMG2
expression in cardiac tissue alone or and in cardiac and vascular smooth muscle tissue together.
However, at higher LT doses, mice lacking CMG2 in all three cell types were more resistant to LT
than cells lacking CMG2 in only cardiac and vascular smooth muscle cells. These results support the
possibility that in this mouse model, LT’s effects on cardiac, vascular smooth muscle and endothelial
cells all contribute to the toxin’s pathogenic effects, although endothelial cells may only contribute
when LT levels are very high. Notably however, while mice lacking CMG2 in all three cell types
together were resistant to B. anthracis spore challenge, ones lacking it in endothelial cells alone,
were not.
Another group studied serial electrocardiograms (ECG), cTnI and echocardiography measures
up to 72 h after low or high doses of LT challenge in Dutch belted rabbits [20]. Some animals were also
sacrificed at 72 h for histology studies. High but not low LT doses were associated with reductions in
MAP first evident at 36 h. Both low and high LT doses were associated with increases in cTnI levels
at 48 and 72 h although ECGs were unchanged. Although quantitative measures were not provided,
light microscopy studies at 72 h were described as showing mild myodegeneration and subacute
inflammation with histiocytes, mononuclear cells, and heterophils present in low dose animals and
acute, multifocal cardiac myocyte necrosis with and without mineralization in the ventricles and
septum in high dose animals. Despite these increases in cTnI and histologic changes, left ventricular
internal diastolic and systolic diameters on echocardiography did not differ from controls in high
dose animals at 48 h (when cTnI levels were highest).
These studies of LT’s effects on myocardial function in in vivo mouse and rat models, while
informative, did not examine this function using methods that controlled for the potential preload
and afterload effects of LT. These studies have also not typically measured pulmonary function to
determine whether respiratory failure itself might have contributed to myocardial changes with LT.
However, a small number of studies have attempted to address these confounding variables.
In a review of their early work, investigators that first reported the effects of LT challenge on
echocardiography measures in the rat described data from six canines with indwelling left ventricular
pressure-volume loop catheters that were observed for up to 96 h after a lethal dose of LT (four
animals) or control (two animals) challenge [55–57]. Using these direct measures, the investigators
noted that a lethal iv LT challenge was associated with progressive increases in end-diastolic pressures
and time of relaxation and a rightward shift of pressure-volume curves with decreases in contractility,
left ventricular ejection fraction, and stroke volume, together suggesting the presence of both systolic
and diastolic dysfunction. Isolated cardiomyocyte contractile function was determined at the time
of the animals’ death or sacrifice and showed a 46% reduction in cell contraction and relaxation in
LT challenged animals. This study appears to be a highly informative one but unfortunately its
findings have only been published in abstract and review form. Much data such as the course of
blood pressure changes occurring in the model would be of considerable value to better assess the
myocardial changes described. Also, while this group had reported that LT caused lung injury in the
rat, pulmonary findings were not described in this canine report [51]. Therefore, whether pulmonary
dysfunction (e.g., hypoxia) contributed to the myocardial changes noted is unclear.
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possible preload, afterload, and pulmonary effects, both  in canines with  indwelling  systemic and 
pulmonary arterial catheters and in isolated rat hearts perfused under constant pressure. In canine 
studies, sedated and mechanically ventilated animals were challenged with 24 h LT infusions and 
serial  cardiopulmonary  measures  were  obtained  for  up  to  96  h  [17].  Compared  to  controls,  
Figure 1. Serial mean effects (˘ SEMs) of 24 h infusions (shaded areas) of low (LD50) or high (LD100)
doses of lethal toxin (LT) compared to protective antigen alone (controls) on changes from baseline in
mean arterial pressure (MAP, panel A), heart rate (HR, panel B), central venous pressure (CVP, panel
C), cardiac index (CI, panel D) and left ventricular ejection fraction (LVEF, panel E). The p-values
shown are for the effects of LT compared to control. Increases or decreases with LT (compared to
controls) are indicated by symbols above or below the dashed horizontal no-effect line respectively.
We have examined the effects of LT on myocardial function while attempting to account for its
possible preload, afterload, and pulmonary effects, both in canines with indwelling systemic and
pulmonary arterial catheters and in isolated rat hearts perfused under constant pressure. In canine
studies, sedated and mechanically ventilated animals were challenged with 24 h LT infusions and
serial cardiopulmonary measures were obtained for up to 96 h [17]. Compared to controls, both lower
LT doses (50% lethal) and higher doses (100% lethal), produced progressive hypotension, increases
in heart rate, and reductions in central venous pressure (CVP). Arterial oxygenation did not decrease
with either low or high doses of LT throughout the 96 h study period. While neither LT dose altered
pulmonary artery occlusion pressure (PAOP), both produced reductions in LVEF first evident 48 h
after the initiation of toxin infusion (Figure 1).
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Cardiac index did not decrease with either toxin dose possibly because HR increased. On the
one hand, decreases in LVEF in the face of unchanged PAOP and the absence of arterial hypoxemia,
suggested that LT had potentially depressed myocardial function directly. However, it was also noted
that daily normal saline volume loads (40 mL/kg over 40 min) were associated with increased LVEF
in animals challenged with high dose LT. This latter finding in combination with the low CVP levels
measured with both toxin doses raised the possibility that changes in preload with LT may have
contributed in part to the reduced LVEF. In the same LT challenged canine model, compared to
no hemodynamic support (fluid and vasopressor therapy titrated to PAOP and MAP respectively)
or hemodynamic support alone, hemodynamic support with a PA directed monoclonal antibody















to  no  hemodynamic  support  (fluid  and  vasopressor  therapy  titrated  to  PAOP  and  MAP 
respectively)  or  hemodynamic  support  alone,  hemodynamic  support  with  a  PA  directed 
monoclonal antibody increased both CVP, LVEF, MAP, and survival [58]. 
 
Figure 2. Serial mean effects  (± SEMs) of  two concentrations of  lethal  toxin  (LT, 50 or 500 ng/mL) 
compared with protective antigen alone (controls) administered to isolated perfused hearts excised 
from healthy animals on left ventricular developed pressure (LVDP, panel A), rate pressure product 
(RPP, panel B)  and  rate  of  change  in LV pressure during  contraction  (dP/dt max, panel C). The 
shaded  area  represents  the  time of LT or  control  administration. The  p‐values  shown are  for  the 
effect of LT versus control.  Increases or decreases with LT  (compared  to controls) are  indicated by 
symbols above or below the dashed horizontal no‐effect  line respectively. The LT concentration of 
50 ng/mL was  comparable  to  a dose previously  shown  to produce  a  50%  lethality  rate  in in vivo 
experiments.  Although  the  concentration  of  500  ng/mL  did  depress  myocardial  function,  this 
represented a dose 10‐fold greater than one producing lethality in vivo. 





did  not  alter  any  parameter measured  including  among  others:  heart  rate  (HR),  left  ventricular 
developed pressure  (LVDP),  rate pressure product  (RPP), dP/dt max, and dP/dt min. Only when 
the concentration of LT was  increased  to  levels 10‐fold  (500 ug/mL) greater  than ones producing 
shock in vivo, were changes seen including decreases in HR, LVDP and dP/dt max and increases in 
dP/dt min (Figure 2). The relevance of these latter changes were unclear however since they were 
evident only with LT concentrations much greater  than  the doses employed in vivo. Furthermore, 
absence  of  changes  in  cardiac  function with  the  lower  LT  concentration may  have  been  due  to 
inadequate observation time to see changes develop. 
To  explore  this  latter  possibility  further,  we  challenged  Sprague‐Dawley  rats  with  a  24  h 
infusion of LT in doses that resulted in 30% lethality rates [60]. At 8, 24, or 48 h after the start of LT 
Figure 2. Serial mean effects (˘ SEMs) of two concentrations of lethal toxin (LT, 50 or 500 ng/mL)
compared with protective antigen alone (controls) administered to isolated perfused hearts excised
from healthy animals on left ventricular developed pressure (LVDP, panel A), rate pressure product
(RPP, panel B) and rate of change in LV pressure during contraction (dP/dt max, panel C). The shaded
area represents the time of LT or control administration. The p-values shown are for the effect of
LT versus control. Increases or decreases with LT (compared to controls) are indicated by symbols
above or below the dashed horizontal no-effect line respectively. The LT concentration of 50 ng/mL
was comparable to a dose previously shown to produce a 50% lethality rate in in vivo experiments.
Although the concentration of 500 ng/mL did depress myocardial function, this represented a dose
10-fold greater than one producing lethality in vivo.
Therefore, to further examine the myocardial effects of LT in a system free of preload and
afterload effects, we isolated hearts from healthy Sprague-Dawley rats and measured their function
while they were perfused over four hours and under constant pressure in a Langendorff system [59].
In these studies, compared to controls exposure of hearts to a concentration of LT in the perfusion
fluid comparable to ones shown to produce shock and lethality in the in vivo rat model (50 ug/mL),
did not alter any parameter measured including among others: heart rate (HR), left ventricular
developed pressure (LVDP), rate pressure product (RPP), dP/dt max, and dP/dt min. Only when the
concentration of LT was increased to levels 10-fold (500 ug/mL) greater than ones producing shock
in vivo, were changes seen including decreases in HR, LVDP and dP/dt max and increases in dP/dt
min (Figure 2). The relevance of these latter changes were unclear however since they were evident
only with LT concentrations much greater than the doses employed in vivo. Furthermore, absence
of changes in cardiac function with the lower LT concentration may have been due to inadequate
observation time to see changes develop.
To explore this latter possibility further, we challenged Sprague-Dawley rats with a 24 h infusion
of LT in doses that resulted in 30% lethality rates [60]. At 8, 24, or 48 h after the start of LT
(or control infusion) animals were randomly selected and had echocardiography performed after
which they were sacrificed and their hearts were isolated and perfused under constant pressure
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in the Langendorff system. On echocardiography, compared to controls, LT challenge decreased
left ventricular ejection fraction (LVEF) at 8 and 48 h but increased it at 24 h in patterns that
differed significantly over time. Lethal toxin also decreased calculated cardiac output (CO) across
the three time points in an overall pattern that was significant. However, once hearts were
isolated from animals and investigated independent of potential preload and afterload effects present
in vivo, prior lethal LT challenge was not associated with significant differences in any parameter,
including HR, LVDP, RPP, dP/dt max, or dP/dt min at any time point compared to controls







ventricular ejection  fraction  (LVEF) at 8 and 48 h but  increased  it at 24 h  in patterns  that differed 
significantly over time. Lethal toxin also decreased calculated cardiac output (CO) across the three 
time points  in  an  overall pattern  that was  significant. However,  once  hearts were  isolated  from 






in LV pressure during contraction  (dP/dt max), and rate pressure product  (RPP)  in hearts excised 
from animals at either 8, 24, or 48 h after the initiation of an in vivo 24 h infusion of lethal toxin (LT) 




Figure 3. Serial mean (˘SEM) left ventricular developed pressure (LVDP), maximum rate of change
in LV pressure during contraction (dP/dt max), and rate pressure product (RPP) in hearts excised
from animals at either 8, 24, or 48 h after the initiation of an in vivo 24 h infusion of lethal toxin (LT)
or protective antigen alone (control) and then perfused under constant pressure. The only significant
difference (p = 0.05) that was noted between LT and control was a decrease in dP/dt max at 60 min
of perfusion.
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Table 2. Summary of functional cardiac findings from preclinical studies in lethal toxin
challenged models.
Publication Subjects Route of LethalToxin Exposure
Functional
Measurement Findings
Watson et al. 2007
[13] Sprague-Dawley rat Intravenous bolus Echocardiography
‚20% increase in
LVAs and LVAd




Watson et al. 2007
[52] Sprague-Dawley rat Intravenous bolus Echocardiography
‚30% reduction in
LVEF in 11/14 rats
surviving after 48 h
related to acute





Cheng et al. 2007 [57] Canine Intravenous bolus Pressure-Volumecatheter
‚Significant LV
dysfunction starting
at 6 h with
development of heart







Moayeri et al. 2009








Sweeney et al. 2010
[17] Purpose–bred Beagle Continuous infusion
PA Catheter
Echocardiography
‚Low and high dose
(see section 4) of LT
caused progressive
declines (15%–20%)
in LVEF at 72 h;
‚No significant
change in PAOP or
SVI with either dose
but CVP decreased
with high dose
Lawrence et al. 2011
[20] Dutch-belted rabbit Intravenous bolus Echocardiography
‚Serial echo
measurements at 0 to















‚No change in LVDP,
RPP, or dP/dt max at
a known lethal dose
of LT;





Liu et al. 2013 [10] Mouse Intraperitoneal Echocardiography
‚Significant decrease
in EF at 48 h after LT
challenge
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Table 2. Cont.
Publication Subjects Route of LethalToxin Exposure
Functional
Measurement Findings
Golden et al. 2013













Li et al. 2015 [60] Sprague-Dawley rat Continuous infusion
Echocardiography





at 8 and 48 h but





exposure to LT no
consistent change at
8, 24, or 48 h in LVSP,
LVDP, RPP, or dP/dt
max or min
CO: Cardiac output, dP/dt: Rate of change in LV pressure during contraction, LVDP: Left ventricular
developed pressure (LVDP = LVSP ´ LVEDP), LVEDP: Left ventricular end diastolic pressure, LVEF: Left
ventricular ejection fraction, LVESP: Left ventricular end systolic pressure, LVSP: Left ventricular systolic
pressure, LVAs: Left ventricular area in systole, LVAd: Left ventricular area in diastole, PAOP: Pulmonary
artery occlusion pressure, RPP: Rate pressure product (LVDPˆHR), SVI: Stroke volume index, VCFC: velocity
of circumferential fiber shortening, Vp: velocity of propagation.
5. Conclusions
As recently noted, the mediators and mechanisms underlying hemodynamic instability during
B. anthracis infection are multifactorial and complex [61]. Likely related to this complexity, findings
from clinical reports in combination with in vivo, in vitro and ex vivo studies provide a mixed picture
as to whether B. anthracis infection is associated with myocardial depression or whether LT itself
can cause this depression directly and independent of its other systemic effects. Interestingly, in
the one clinical report providing both echocardiography and pulmonary arterial catheter data in a
patient requiring vasopressor therapy and who ultimately died, left ventricular dysfunction other
than that related to a progressive pericardial effusion appeared minimal [18]. While data from
echocardiography studies in other patients are more limited, several reports from patients with
severe disease have also not been remarkable [19,37]. In those reports where dysfunction has been
noted, whether this was related to prior disease in older patients or to infection itself is unclear since
follow-up studies after resolution of infection were not provided. Comparison of animal studies with
LT alone may be difficult to interpret based on the multiple factors that differed between them (e.g.,
differing species and models employed and methods of toxin administration) as well as the fact that
many of these studies did not account for changes in preload and afterload with LT or with changes
in pulmonary function. However, even in models accounting for such influence, the effects of LT on
cardiac function have been variable.
In conclusion, if LT does contribute to shock during anthrax infection, presently available clinical
data do not provide strong evidence that this compromise is related to direct myocardial depression.
However, efforts should continue to be made to further understand the impact of LT on myocardial
function in anthrax sepsis both clinically and in preclinical models. This question carries important
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implications not only for the conventional management of patients with anthrax infection and shock
but also for the development of new and targeted therapies.
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